-
-
-
-
-
-
-
Candel reports extended survival in lung cancer trial
-
-
-
-
-
-
-
Stephens Starts Candel Therapeutics Inc. (CADL) at Overweight
-
-
-
-
-
-
-
Candel Therapeutics (CADL) Files $300M Mixed Shelf
-
-
-
-
-
-
-
Candel Therapeutics (CADL) Appoints Charles Schoch as CFO
-
-
-
-
-
-
-
Candel Therapeutics (CADL) Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care
-
-
-
-
-
-
-
Candel Therapeutics Inc. (CADL) PT Raised to $19 at H.C. Wainwright
-
-
-
-
-
-
-
Candel Therapeutics (CADL) to Join Russell 3000 Index
437,342 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

